Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RQ 3013

Next Previous
Drug Profile

RQ 3013

Alternative Names: 2019-nCov vaccine - Shanghai RNACure Biopharma; RQ-3013; SARS-CoV-2 mRNA Chimera Vaccine - Walvax Biotechnology/Shanghai RNACure Biopharma

Latest Information Update: 24 Jun 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Walvax Biotechnology
  • Class COVID-19 vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 03 Jun 2022 Preclinical trials in COVID-2019 infections in China (IM) (Walvax Biotechnology pipeline, June 2022)
  • 27 May 2022 Walvax Biotechnology and Shanghai RNAcure Biopharma plans a phase I trial for COVID-2019 infections (Prevention) in June 2022 (IM) (NCT05394012)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top